Therefore, other trials have already combined PLK-1 inhibitors with either low-dose cytarabine or hypomethylating agents like decitabine in patients with relapsed/refractory AML or ineligible for intensive chemotherapy, resulting in an increase in the anti-leukemic potential [75]. Here, PLK1 is linked to acute myeloid leukemia.